Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study

Vandana Singh
1 min read
0
In this article:

  • HUTCHMED (China) Limited (NASDAQ: HCM) announced initial results from FRUTIGA Phase 3 trial of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

  • The trial met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful.

  • The other primary endpoint of overall survival (OS) was not statistically significant per the pre-specified statistical plan, although there was an improvement in median OS.

  • Related: HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer.

  • Fruquintinib also demonstrated a statistically significant improvement in secondary endpoints, including objective response rate (ORR), disease control rate (DCR), and improved duration of response (DoR).

  • The safety profile of fruquintinib in FRUTIGA was consistent with previously reported studies.

  • Full detailed results are subject to ongoing analysis and are expected to be disclosed at an upcoming scientific meeting. T

  • HUTCHMED retains all commercial rights to fruquintinib outside of China. In China, fruquintinib is marketed under the brand name Elunate. HUTCHMED is partnered with Eli Lilly And Co (NYSE: LLY).

  • Price Action: HCM shares are up 15.60% at $11.44 during the premarket session on the last check Monday.

 

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories